Parkinson’s Disease PBMC
Parkinson's Disease PBMC samples are collected from IRB-consented donors with clinically confirmed Parkinson's disease and cryopreserved in CryoStor CS10. Ideal for peripheral immune profiling, transcriptomics, mitochondrial and lysosomal pathway assays, LRRK2 and GBA1 genotyping, and iPSC reprogramming. Age- and sex-matched healthy controls available.
| Lot # | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 78360 | Parkinson's Disease | 10M | 71 | Male | Ukraine |
Acetylsalicylic acid, Carbidopa/levodopa
|
1 | |||
| 78361 | Parkinson's Disease | 10M | 71 | Male | Ukraine |
Acetylsalicylic acid, Carbidopa/levodopa
|
1 | |||
| 78362 | Parkinson's Disease | 10M | 71 | Male | Ukraine |
Acetylsalicylic acid, Carbidopa/levodopa
|
1 | |||
| 78363 | Parkinson's Disease | 10M | 71 | Male | Ukraine |
Acetylsalicylic acid, Carbidopa/levodopa
|
1 | |||
| 78377 | Parkinson's Disease | 10M | 74 | Female | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | |||
| 78378 | Parkinson's Disease | 10M | 74 | Female | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | |||
| 78379 | Parkinson's Disease | 10M | 74 | Female | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | |||
| 78380 | Parkinson's Disease | 10M | 74 | Female | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | |||
| 78429 | Parkinson's Disease | 10M | 72 | Male | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | |||
| 78430 | Parkinson's Disease | 10M | 72 | Male | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 |
Parkinson’s Disease PBMC for Neurodegeneration and Peripheral Immunology Research
Parkinson’s Disease Human PBMC products are sourced from IRB-consented donors clinically diagnosed with Parkinson’s disease, processed within 24 hours of collection and cryopreserved in CryoStor CS10. These peripheral blood mononuclear cells support genetic, transcriptomic and cellular immunology work in a neurodegenerative disease.
Parkinson’s Disease Biology and Why PBMC
Parkinson’s disease is a neurodegenerative disorder, not an autoimmune disease. Its defining pathology is progressive loss of dopaminergic neurons in the substantia nigra together with intracellular alpha-synuclein aggregation.
- Alpha-synuclein misfolding and aggregation into Lewy pathology is the central molecular event, and peripheral cells are used to study handling of alpha-synuclein and related proteostasis machinery
- Loss of nigrostriatal dopaminergic neurons produces the motor phenotype and underlies dopaminergic pharmacotherapy
- Common genetic risk variants in LRRK2 and GBA1 are among the best established in the field, and PBMC provide accessible genomic DNA and matched living cells from carriers
- Mitochondrial and lysosomal-autophagy pathway dysfunction, including PINK1 and PRKN biology, is measurable in peripheral mononuclear cells
- Peripheral immune involvement is an active research area rather than a settled mechanism: altered monocyte and T cell phenotypes have been reported in Parkinson’s cohorts, and this is the main scientific justification for a PBMC product
- PBMC also support iPSC reprogramming for patient-derived neuronal models, plus flow cytometry, single-cell RNA sequencing and ex vivo functional assays
Donor Stratification Available
- Disease stage by clinician assessment, where recorded
- Disease duration since diagnosis
- Genetic status where available, including LRRK2 and GBA1 variant carriers
- Treatment status: levodopa-treated, dopamine agonist-treated, or treatment-naive
- Motor phenotype, including tremor-dominant versus postural instability and gait difficulty
- Presence or absence of documented cognitive involvement
- Matched healthy controls available, age- and sex-matched on request
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed Parkinson’s disease donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified Parkinson’s disease diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Medication history, including dopaminergic therapy
- Additional Parkinson’s disease-specific data available upon request
Applications
- Peripheral immune cell phenotyping in neurodegeneration
- Single-cell and bulk transcriptomic profiling
- Genomic DNA extraction for LRRK2, GBA1 and polygenic risk genotyping
- Mitochondrial function and mitophagy assays in primary human cells
- Lysosomal and autophagy pathway research, including glucocerebrosidase activity
- iPSC reprogramming and patient-derived neuronal model generation
- Target validation and compound screening for disease-modifying candidates
- Biomarker discovery against age- and sex-matched healthy controls
Other Parkinson’s Disease Specimen Types
- Parkinson’s Disease Plasma
- Parkinson’s Disease Serum
- Parkinson’s Disease Whole Blood
- Parkinson’s Disease Cerebrospinal Fluid
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Customization
Parkinson’s Disease PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability, international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To browse PBMC from other disease states and check live stock status, visit our human PBMC page.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.